Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line

Molecular Pharmacology

Volumn 57, Issue 3, 2000, Pages 503-511

  Pestell, Katharine E ^a   Hobbs, Stephen M ^a   Titley, Jenny C ^a   Kelland, Lloyd R ^a   Walton, Michael I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; CISPLATIN; DNA; PROTEIN P53; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; TRANSPLATIN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CONTROLLED STUDY; DNA ADDUCT; DNA DRUG COMPLEX; DNA REPAIR; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0034006177     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.57.3.503     Document Type: Article

References (38)

1. Adams M, Calvert AH, Carmichael J, Clark PI, Cloeman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJS, Slevin ML, Smyth JF, Thoman H and Wilkinson PM (1998) Chemotherapy for ovarian cancer: A consensus statement on standard practice. Br J Cancer 78:1404-1406.
2. Amundson SA, Myers TG and Fornace AJ (1998) Roles for P53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene 17:3287-3299.
3. Andrews PA, Velury S, Mann SC and Howell SB (1988) cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68-73.
4. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtêsec B and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55:678-684.
5. 2 arrest after DNA damage. Science (Wash DC) 282:1497-1501.
6. Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by RAS and p53. Science (Wash DC) 255:459-462.
7. Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299.
8. Chu G (1994) Cellular responses to cisplatin. J Biol Chem 269:787-790.
9. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Siré E, Arzani D. Stanzione S, Parodi S, D'Incalci M, Russo P and Broggini M (1997) DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76:474-479.
10. Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, Ellmore NW, Galen AT, Lautenberger JA, Papas TS, Westin EH, Wong-Stall F, Gallo RC and Aaronson SA (1982) Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature (Lond) 295:116-119.
11. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ and O'Connor PM (1997) Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127-2136.
12. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654.
13. Fort P, Marty L, Piechaczyk M, El Sabrouty S, Dani C, Jeanteur P and Blanchard JM (1983) Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13:1431-1432.
14. Fritsche M, Haessler C and Brandner G (1993) Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318.
15. Graniela Siré EA, Vikhanskaya F and Broggini M (1995) Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann Oncol 6:589-593.
16. Hawkins DS, Demers GW and Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 58:892-898.
17. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178-2184.
18. Holford J, Sharp SY, Murrer BA, Abrams M and Kelland LR (1998) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77:366-373.
19. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science (Wash DC) 253:49-53.
20. Ju J-F, Banerjee D, Lenz H-J, Danenberg KD, Schmittgen TC, Spears CP, Schönthal AH, Manno DJ, Hochhauser D, Bertino JR and Danenberg PV (1998) Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 4:1315-1322.
21. Keen N, Elston R and Crawford L (1994) Interaction of the E6 protein of human papillomavirus with cellular proteins. Oncogene 9:1493-1499.
22. Kelland LR, Barnard CFJ, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA and Harrap KR (1994) A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res 54:5618-5622.
23. Kimura M, Tagawa M, Takenaga K, Yamaguchi T, Saisho H, Nakagawara A and Sakiyama S (1997) Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res 17:879-884.
24. Kubbutat MH and Vousden KH (1998) Keeping an old friend under control: Regulation of p53 stability. Mol Med Today 4:250-256.
25. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant after irradiation. Proc Natl Acad Sci USA 89:7491-7495.
26. Mellish KJ, Barnard CFJ, Murrer BA and Kelland LR (1995) DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 62:717-723.
27. Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
28. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
29. Oren M, Maltzman W and Levine AJ (1981) Post-translational regulation of the 54K cellular tumor-antigen in normal and transformed cells. Mol Cell Biol 1:101-110.
30. Pestell KE, Medlow CJ, Titley JC, Kelland LR and Walton MI (1998) Characterisation of the P53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77:913-918.
31. Piovesan B, Pennell N and Berinstein NL (1998) Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Oncogene 17:2339-2350.
32. Scheffner M, Werness BA, Huibregste JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
33. Shelling AN, Cooke IE and Ganesan TS (1995) The genetic analysis of ovarian cancer. Br J Cancer 72:521-527.
34. Skehan P, Storeg R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J, Bokesch H, Kenney S and Boyd M (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
35. Smith ML, Chen I-T, Zhan G, O'Connor PM and Fornace AJ Jr (1995) Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10: 1053-1059.
36. Van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B and Reutelingsperger CPM (1998) Annexin V-affinity assay.-A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9.
37. Waldman T, Lengauer C, Kinzler ICW and Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond) 381:713-716.
38. Wu GS and El Diery WS (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res 2:623-633.